

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt as to any aspect of the proposals referred to in this notice or as to the action you should take, please take advice from a stockbroker, solicitor, accountant or other independent professional adviser.

If you have sold or otherwise transferred all of your shares, please send this document, together with the enclosed documents, at once to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Whether or not you propose to attend the AGM, please complete and submit a form of proxy in accordance with the instructions printed on the enclosed form (the "Form of Proxy"). The Form of Proxy must be received not less than 48 hours before the time of the holding of the AGM (i.e. by 3:00 p.m. (London time) on June 17, 2019).



**NOTICE OF THE ANNUAL GENERAL MEETING
OF MERO BIOPHARMA GROUP PLC (THE "COMPANY")**

to be held at the Marlborough Theatre, The King's Fund, 11–13 Cavendish Square, London W1G 0AN, United Kingdom
on Wednesday June 19, 2019 at 3:00 p.m. (London time) (the "AGM")

Cautionary note regarding forward-looking statements

This document contains statements about the Company that are or may be "forward-looking statements". All statements, other than statements of historical facts, included in this document may be forward-looking statements. Without limitation, any statements preceded or followed by, or that include, the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "should", "anticipates", "estimates", "projects" or words or terms of similar substance, or the negative thereof, are forward-looking statements. These forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of the Company. These factors are discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended 31 December 2018. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person, or industry results, to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate in the future. Past performance is not a guarantee of future performance. Investors should not place undue reliance on such forward-looking statements and, save as is required by law or regulation (including to meet the requirements of the AIM Rules for Companies, the Market Abuse Regulation, and/or the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update publicly or revise any forward-looking statements (including to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based). All subsequent forward-looking statements attributed to the Company or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements contained in this document are based on information available to the Directors of the Company at the date of this document, unless some other time is specified in relation to them, and the posting or receipt of this document shall not give rise to any implication that there has been no change in the facts set forth herein since such date.

Notice to overseas persons

The distribution of this document in certain jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Contents

Letter from the Chairman of Mereo BioPharma Group plc
Notice of Annual General Meeting

3
7



Letter from the Chairman of Mereo BioPharma Group plc

(Registered and incorporated in England and Wales with Company number 09481161)

Registered Office:
4th Floor,
One Cavendish Place,
London W1G 0QF
20 May 2019

Directors

Dr. Peter Fellner	(Non-Executive Chairman)
Dr. Denise Scots-Knight	(Chief Executive Officer)
Richard Jones	(Chief Financial Officer)
Peter Bains	(Non-Executive Director)
Paul Blackburn	(Non-Executive Director)
Dr. Anders Ekblom	(Non-Executive Director)
Kunal Kashyap	(Non-Executive Director)
Dr. Deepa Pakianathan	(Non-Executive Director)
Michael Wyzga	(Non-Executive Director)

(together, the "**Directors**")

Dear Shareholder,

Notice of 2019 Annual General Meeting

1. Introduction

The purpose of this document is to provide you with details of the resolutions to be proposed at the AGM of the Company to be held on June 19, 2019 at 3:00 p.m. (London time) and convened by the formal Notice of Annual General Meeting set out on pages 7 to 11 of this document.

In addition to highlighting the usual business to be transacted at the AGM, this letter explains the background to the resolutions which will be considered at the AGM, why the Directors consider the resolutions to be in the best interests of shareholders of the Company as a whole and why they recommend that you vote in favour of the resolutions.

2. Resolutions

The business to be conducted at the AGM consists of consideration of the following resolutions. Resolutions 1 to 6 are proposed as ordinary resolutions. This means that for each of those resolutions to be passed, more than half of the votes cast must be in favour of the resolution. Resolution 7 is proposed as a special resolution. This means that for this resolution to be passed, at least three-quarters of the votes cast must be in favour of the resolution.

Resolution 1 – Annual Report and Accounts

This resolution is proposed as an ordinary resolution.

The Directors are obliged to lay the annual financial statements, the directors' report and the independent auditor's report before shareholders each financial year at a general meeting.

Resolutions 2 and 3 – Appointment and remuneration of Ernst & Young LLP

These resolutions are proposed as ordinary resolutions.

The Company is required to appoint auditors at each general meeting at which accounts are laid before the shareholders to hold office until the next such meeting.

Resolution 2 proposes the re-appointment of Ernst & Young LLP as auditors of the Company.

Resolution 3 authorises the Directors to determine Ernst & Young LLP's remuneration.

You are asked to authorise the directors to re-appoint Ernst & Young LLP as auditors and to authorise the Directors to determine their remuneration. Ernst & Young LLP have indicated that they are willing to continue to act as the Company's auditors for a further year.

Resolutions 4 and 5 – Re-appointment of Dr. Deepa Pakianathan and Michael Wyzga

These resolutions are proposed as ordinary resolutions.

Dr. Deepa Pakianathan and Michael Wyzga were appointed as directors of the Company with effect from completion of the Company's merger with OncoMed Pharmaceuticals, Inc. on April 23, 2019. In accordance with Article 29.1 (a) of the Company's articles of association, any director who has been appointed by the Directors since the previous Annual General Meeting shall retire from office but be eligible for re-appointment. A biography for each of Dr. Deepa Pakianathan and Michael Wyzga is included in the 2018 Annual Report published on April 30, 2019 and is available from the Company's Investor Relations website (www.mereobiopharma.com/investors/). The Directors believe that Deepa and Michael bring a wealth of experience to the Board and therefore consider it entirely appropriate for them to seek re-appointment at the AGM.

Resolution 6 – Authority to allot shares

This resolution is proposed as an ordinary resolution.

Under the Companies Act 2006, the directors of a company may only exercise the powers of the Company to allot shares of the Company, or grant rights to subscribe for, or to convert securities into, shares of the Company (other than in connection with an employee share scheme) if authorised to do so by the shareholders in a general meeting. The authority which is sought in respect of this is set out in resolution 6, which would allow the Directors to allot new shares or grant rights to subscribe for, or convert other securities into, shares up to an amount equal to 100% of the current total issued ordinary share capital of the Company. As at May 17, 2019, being the latest practicable date prior to publication of this document, the total issued share capital of the Company comprises ordinary shares with an aggregate nominal value of £288,070.78.

This authority is sought for the reasons outlined in paragraph 3 below and, if approved, would last until the next Annual General Meeting of the Company or, if earlier, 15 months from the date of the passing of this resolution.

Resolution 7 – Disapplication of pre-emption rights

This resolution is proposed as a special resolution.

Under section 561(1) of the Companies Act 2006, if the Directors wish to allot ordinary shares, or grant rights to subscribe for, or convert securities into, ordinary shares (which for this purpose includes a sale of treasury shares for cash), other than pursuant to an employee share scheme, they must in the first instance offer them to existing ordinary shareholders in proportion to their holdings. There may be occasions, however, when the Directors need the flexibility to finance business opportunities by the issue of shares for cash without a pre-emptive offer to existing shareholders, as noted in greater detail in paragraph 3 below. This cannot be done under the Companies Act 2006 unless the shareholders have first waived their pre-emption rights.

Resolution 7 would allow the Directors to allot equity securities for cash without first being required to offer them to existing ordinary shareholders. If approved, the resolution would authorise the Directors to allot ordinary shares, or grant rights to subscribe for, or convert securities into, ordinary shares up to an aggregate maximum nominal amount of £288,070.78 (which includes, for this purpose, the sale on a non-pre-emptive basis of any shares held in treasury), representing 100% of the issued share capital of the Company calculated as at May 17, 2019, the latest practicable date prior to the publication of this document, as if section 561(1) of the Companies Act 2006 did not apply to such allotment or grant or sale of treasury shares.

This power is sought for the reasons outlined in paragraph 3 below and, if approved, would last until the next Annual General Meeting of the Company or, if earlier, 15 months from the date of the passing of this resolution.

3. Reasons for Resolutions 6 and 7

The Company's strategy continues to be to build a portfolio of rare disease products acquired from pharmaceutical and large biotechnology companies and to develop these through regulatory approval and subsequent commercialisation.

Rare (and orphan) diseases represent an attractive development and commercialisation opportunity for the Company, since they typically have high unmet medical need and can often utilise regulatory pathways that facilitate acceleration to the potential market. Development of rare disease products generally involves close co-ordination with patient organisations and key opinion leaders and investigators. Patients are typically treated at a limited number of specialised sites, which helps identification of the patient population and enables a small and targeted sales infrastructure to commercialise the products in key markets.

The Company plans to partner or sell our existing non-rare disease products prior to commercialisation, recognising the need for a larger sales infrastructure and greater resources to take these products to market.

We have made significant progress across all our programs both in terms of clinical development and regulatory strategy. We were pleased to announce positive results from our Phase 2b study and extension study in Hypogonadotropic Hypogonadism (HH) in March 2018 and December 2018, the completion of enrollment of 112 patients into our adult Phase 2b study in Osteogenesis Imperfecta (OI) and the initiation of our 165 patient Phase 2 study into severe Alpha-1 Antitrypsin Deficiency (severe AATD) in Q4 2018. We were also admitted to the PRIME pathway in Europe, a regulatory process in Europe that is designed to provide faster access to medicines for patients as a result of an interactive dialogue with the EMA during development that results in accelerated approval timelines. With both our OI and severe AATD Phase 2 programs well underway, we continue to expect to deliver some important clinical data on our two core rare disease products in 2019.

The merger with OncoMed Pharmaceuticals, Inc. completed on April 23, 2019 and significantly extended our cash runway into 2020. This will enable us to deliver on the key milestones for our two rare disease product candidates BPS-804 and MPH-966.

In order to provide the flexibility to access additional capital when market conditions are appropriate, the Directors believe that it is in the best interests of the Company to be prepared in advance and have the ability to raise funds by issuing shares or other securities without the need to convene a general meeting should they determine that it is appropriate to do so. The authority and power proposed in resolutions 6 and 7 would allow the Company to better compete for capital against other companies incorporated in the US and elsewhere which are not subject to allotment or pre-emption restrictions such as those applicable to companies incorporated in England and Wales. Together with our recent ADS listing on Nasdaq (which facilitates investment in the Company from a broad number of specialised US healthcare investors), the Directors believe that this authority and power will significantly strengthen the Company's ability to compete with its competitors.

The authority and power that will be granted to the Directors, if resolutions 6 and 7 are passed, are primarily being requested to allow for the issue of shares (and, indirectly, ADSs), but would, if passed, also allow for the issue of other securities, including, for example, awards granted under the Company's share schemes relating to non-employees.

This authority and power proposed would be in addition to the existing equivalent authority and power of June 2, 2016. The Directors consider that this is appropriate because substantially all of the Company's existing equivalent authority and power could be required to fulfil a number of existing contractual obligations, including obligations under certain of the Company's share schemes and obligations to issue shares pursuant to the contingent value rights agreement executed in connection with the Company's merger with OncoMed Pharmaceuticals, Inc.


4. Action to be taken

You will find a form of proxy enclosed with this document for use in connection with the AGM. Whether or not you intend to be present at the AGM, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon as soon as possible. To be valid, completed forms of proxy must be completed and received by the Company's registrars, Link Asset Services at PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF, United Kingdom not later than 3:00 p.m. (London time) on June 17, 2019, being 48 hours before the time appointed for holding the AGM or completed electronically in accordance with the notes to this document. Completion of the form of proxy will not preclude you from attending the AGM and voting in person if you so wish.

5. Recommendation

The Directors consider that the resolutions to be proposed at the AGM are in the best interests of the Company and its shareholders as a whole and are likely to promote the success of the Company. The Directors unanimously recommend that you vote in favour of the proposed resolutions as they intend to do in respect of their own beneficial holdings, which amount to approximately 4.0% of the voting rights of the current issued ordinary share capital of the Company.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'P. S. I' followed by a stylized flourish.

Peter Fellner
Chairman

MEREO BIOPHARMA GROUP PLC

(the "Company")

(Registered and incorporated in England and Wales with company number 09481161)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that an Annual General Meeting (the "AGM") of the Company will be held at the Marlborough Theatre, The King's Fund, 11–13 Cavendish Square, London W1G 0AN, United Kingdom on Wednesday June 19, 2019 at 3:00 p.m. (London time) to consider and, if thought fit, to pass the resolutions below. Resolution 7 will be proposed as a special resolution, with the remainder being proposed as ordinary resolutions.

1. That the annual report and accounts for the financial year ended December 31, 2018, together with the directors' report and independent auditors' report thereon, be received and adopted.
2. That Ernst & Young LLP be re-appointed as auditors to hold office from the conclusion of this AGM until the conclusion of the next Annual General Meeting at which the Company's annual report and accounts are presented.
3. That the directors of the Company (the "Directors") be authorised to determine Ernst & Young LLP's remuneration.
4. That Deepika Pakianathan be re-appointed as a director of the Company.
5. That Michael Wyzga be re-appointed as a director of the Company.
6. That, in addition to any authority previously conferred upon the Directors pursuant to section 551 of the Companies Act 2006 (the "Act"), the Directors be generally and unconditionally authorised in accordance with section 551 of the Act to exercise all the powers of the Company to allot shares in the Company or to grant rights to subscribe for, or to convert any securities into, shares in the Company up to a maximum aggregate nominal amount of £288,070.78, such authority to expire at the end of the next Annual General Meeting of the Company or, if earlier, 15 months from the date of the passing of this resolution, save that the Company may, before such expiry, make offers or agreements which would, or might, require shares to be allotted or rights to subscribe for or to convert any securities into shares to be granted after such expiry and the Directors may allot shares or grant such rights under any such offer or agreement as if the authority conferred by this resolution had not expired.
7. That, subject to the passing of resolution 6 and in addition to any power previously conferred upon the Directors pursuant to Chapter 3 of Part 17 of the Act, the Directors be generally empowered pursuant to section 570 and section 573 of the Act to allot equity securities (as defined in section 560 of the Act) for cash pursuant to the authority given by resolution 6 and to sell equity securities held as treasury shares for cash pursuant to section 727 of the Act, in each case as if section 561(1) of the Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment or sale of equity securities up to an aggregate nominal value of £288,070.78, such power to expire at the end of the next Annual General Meeting of the Company or, if earlier, 15 months from the date of the passing of this resolution, save that the Company may, before such expiry, make offers or agreements which would or might require equity securities to be allotted and equity securities held as treasury shares to be sold after such expiry, and the Directors may allot equity securities and sell equity securities held as treasury shares in pursuance of any such offer or agreement as if the power conferred hereby had not expired.

BY ORDER OF THE BOARD



Charles Sermon
Company Secretary
May 20, 2019

REGISTERED OFFICE
4th Floor
One Cavendish Place
London W1G 0QF

Notes:**Entitlement to attend and vote**

1. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, the Company specifies that only those shareholders registered on the Company's register of members at:
 - a. close of business on June 17, 2019; or
 - b. if the AGM is adjourned, close of business on the day that is two days prior to the adjourned meeting,shall be entitled to attend and vote at the AGM or adjourned meeting (as applicable) in respect of the number of ordinary shares registered in their name at the time.

Changes to entries on the register of members after this time shall be disregarded in determining the rights of any person to attend or vote at the AGM.

Website giving information regarding the AGM

2. Information regarding the AGM can be found at <https://www.mereobiopharma.com/investors>.

Appointment of proxies

3. If you are a shareholder of the Company at the time set out in note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the AGM and you should have received a form of proxy with this notice of AGM. You can only appoint a proxy using the procedures set out in these notes and the notes to the form of proxy.
4. A proxy does not need to be a shareholder of the Company but must attend the AGM to represent you. Details of how to appoint the Chairman of the AGM or another person as your proxy using the form of proxy are set out in the notes to the form of proxy. If you wish your proxy to speak on your behalf at the AGM you will need to appoint your own choice of proxy (not the Chairman) and give your instructions directly to them.
5. You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. If you are appointing more than one proxy you must indicate the number of shares in respect of which you are making this appointment. You should include the number in the box provided for your first named proxy and either obtain (an) additional form(s) of proxy from the registrar of the Company at Link Asset Services, PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF, United Kingdom or you may photocopy the form of proxy. Please return all the forms together and tick the box to indicate each form is one of multiple instructions being given. Please take care when completing the number of shares; if the total number of shares exceeds the total number held by the shareholder, all appointments may be invalid. All forms of proxy must be signed and should be returned together in the same envelope.

6. Appointment of a proxy does not preclude a shareholder from attending the AGM and voting in person. If you wish to attend the AGM in person, please bring with you the attendance card accompanying this notice of AGM. This will authenticate your right to attend, speak and vote at the AGM and assist us in registering your attendance without delay.
7. The right to appoint a proxy does not apply to persons whose shares are held on their behalf by another person and who have been nominated to receive communications from the Company in accordance with Section 146 of the Companies Act 2006 (nominated persons). Nominated persons may have a right under an agreement with the registered shareholder who holds the shares on their behalf to be appointed (or to have someone else appointed) as a proxy. Alternatively, if nominated persons do not have such a right, or do not wish to exercise it, they may have a right under such an agreement to give instructions to the person holding the shares as to the exercise of voting rights.

Appointment of proxy using hard copy form of proxy

8. The notes to the form of proxy explain how to direct your proxy to vote on the resolution or withhold their vote. To validly appoint a proxy using the form of proxy, the form must be:
 - a. completed and signed; and
 - b. sent or delivered to the Company's registrar's address at Link Asset Services, PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF, United Kingdom not less than 48 hours before the time appointed for holding the AGM or adjourned meeting to which it relates.
9. In the case of a poll taken more than 48 hours after it is demanded, the form of proxy must be delivered to PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF, United Kingdom not less than 24 hours before the time appointed for the taking of the poll. In the case of a poll not taken during the AGM but taken not more than 48 hours after it was demanded, the form of proxy must be delivered:
 - a. in accordance with note 1 above; or
 - b. at the meeting at which the poll was demanded to the Chairman, secretary or any director.
10. In the case of a shareholder which is a company, the form of proxy must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company.
11. Any power of attorney or any other authority under which the form of proxy is signed (or a duly certified copy of such power of authority) must be included with the form of proxy not less than 48 hours before the time appointed for holding the AGM or adjourned meeting to which it relates.

Appointment of proxy electronically

12. As an alternative to completing the hard-copy form of proxy, you can appoint a proxy electronically by visiting www.signalshares.com. You will be asked to enter your Investor Code shown on your share certificate and agree to certain terms and conditions. For an electronic proxy appointment to be valid, your appointment must be received by Link Asset Services not less than 48 hours before the time appointed for holding the AGM or adjourned meeting to which it relates.

Appointment of proxies through CREST

13. CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic appointment service, may do so for the AGM and any adjournment(s) thereof by utilising the procedures described in the "CREST Reference Manual" issued by Euroclear UK & Ireland Limited (the "**CREST Manual**"). CREST personal members or other CREST sponsored members and those CREST members who have appointed (a) voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.
14. In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message must be properly authenticated in accordance with Euroclear UK & Ireland Limited's specifications and must contain the information required for such instructions, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by the issuer's agent, Link Asset Services (ID: RA10) by the latest time for receipt of proxy appointments specified in these notes. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.
15. CREST members and, where applicable, their CREST sponsors or voting service provider(s) should note that Euroclear does not make available special procedures in CREST proxy instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service provider(s) are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
16. The Company may treat as invalid a CREST proxy instruction in the circumstances set out in Regulation 35(5) (a) of the Uncertificated Securities Regulations 2001.

Appointment of proxy by joint holders

17. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).

Changing proxy instructions

18. To change your proxy instructions simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded.
19. Where you have appointed a proxy using the hard-copy form of proxy and would like to change the instructions using another hard-copy form of proxy, please contact Link Asset Services at PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF, United Kingdom.
20. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

Termination of proxy appointments

21. Any appointment under a form of proxy may only be revoked by delivering a notice in writing given by or on behalf of the person by whom or on whose behalf the form of proxy was given to PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF, United Kingdom.
22. A notice revoking a proxy appointment only takes effect if it is delivered before:
 - a. the start of the AGM or adjourned meeting to which it relates; or
 - b. (in the case of a poll not taken on the same day as the AGM or adjourned meeting) the time appointed for taking the poll to which it relates.
23. Appointment of a proxy does not preclude you from attending the AGM (or any adjournment thereof) and voting in person. If you have appointed a proxy and attend the AGM (or any adjournment thereof) in person, your proxy appointment will automatically be terminated.

Corporate representatives

24. A corporation which is a shareholder can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a shareholder provided that no more than one corporate representative exercises powers over the same ordinary shares.

Verification of identity

25. Shareholders, proxies and authorised representatives will be required to provide their names and addresses for verification against the register of members and proxy appointments received by the Company before entering the AGM. Each authorised representative must produce proof of his or her appointment, in the form of the actual appointment or a certified copy. Other than this, there are no procedures with which any such persons must comply in order to attend and vote at the AGM.

Issued shares and total voting rights

26. As at close of business on the day immediately prior to the date of posting of this notice of AGM, the Company's issued share capital comprised 96,023,592 ordinary shares. Each ordinary share carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at close of business on the day immediately prior to the date of posting of this notice of AGM is 96,023,592.

Electronic address

27. You may not use any electronic address (within the meaning of Section 333(4) of the Companies Act 2006) provided in this notice of AGM (or in any related documents including the form of proxy) to communicate with the Company for any purposes other than those expressly stated.



MEREO BIOPHARMA GROUP PLC

4th Floor
One Cavendish Place
London W1G 0QF
United Kingdom